The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series)

Pulmonary Circulation

Volumn 4, Issue 2, 2014, Pages 200-210

  Maron, Bradley A ^a,b   Leopold, Jane A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Angiotensin II; Mineralocorticoid receptor; Pulmonary arterial hypertension; Spironolactone

Indexed keywords

EID: 85026336684     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/675984     Document Type: Review

References (88)

1. Ling Y, Johnson MK, Kiely DG, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012;186:790-796.
2. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-163.
3. Voelkel NF, Cool C. Pathology of pulmonary hypertension. Cardiol Clin 2004;22:343-351, v.
4. McLaughlin VV. Looking to the future: a new decade of pulmonary arterial hypertension therapy. Eur Respir Rev 2011; 20:262-269.
5. Davies RJ, Morrell NW. Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morpho-genetic protein type II receptor. Chest 2008;134:1271-1277.
6. Rubin LJ, Simonneau G, Badesch D, et al. The study of risk in pulmonary arterial hypertension. Eur Respir Rev 2012; 21:234-238.
7. Beuschlein F. Regulation of aldosterone secretion: from physiology to disease. Eur J Endocrinol 2013;168:R85-R93.
8. Sulya LL, McCaa CS, Read VH, Bomer D. Uptake of triti-ated aldosterone by rat tissues. Nature 1963;200:788-789.
9. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004;351:33-41.
10. Lieb W, Xanthakis V, Sullivan LM, et al. Longitudinal tracking of left ventricular mass over the adult life course: clinical correlates of short-and long-term change in the framingham offspring study. Circulation 2009; 119: 3085-3092.
11. Pitt B, Zannad F, Remme WJ, et al. The effect of spi-ronolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
12. Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol 2008;93:519-527.
13. Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 2010;6:261-273.
14. Batt J, Shadly Ahmed S, Correa J, Bain A, Granton J. Skeletal muscle dysfunction in idiopathic pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2014;50:74-86.
15. Oki K, Kopf PG, Campbell WB, et al. Angiotensin II and III metabolism and effects on steroid production in the HAC15 human adrenocortical cell line. Endocrinology 2013;154: 214-221.
16. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000;52:639-672.
17. Zhang F, Hu Y, Xu Q, Ye S. Different effects of angiotensin II and angiotensin-(1-7) on vascular smooth muscle cell proliferation and migration. PLoS One 2013;5:e12323.
18. Morrell NW, Atochina EN, Morris KG, Danilov SM, Stenmark KR. Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. J Clin Invest 1995; 96: 1823-1833.
19. de Man FS, Tu L, Handoko ML, et al. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186: 780-789.
20. Li G, Liu Y, Zhu Y, et al. ACE2 activation confers endothe-lial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats. Lung 2013;191:327-336.
21. Morrell NW, Upton PD, Higham MA, Yacoub MH, Polak JM, Wharton J. Angiotensin II stimulates proliferation of human pulmonary artery smooth muscle cells via the AT1 receptor. Chest 1998;114:90S-91S.
22. Morrell NW, Upton PD, Kotecha S, et al. Angiotensin II activates MAPK and stimulates growth of human pulmonary artery smooth muscle via AT1 receptors. Am J Physiol 1999;277:L440-L448.
23. Orte C, Polak JM, Haworth SG, Yacoub MH, Morrell NW. Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J Pathol 2000;192:379-384.
24. Morrell NW, Danilov SM, Satyan KB, Morris KG, Stenmark KR. Right ventricular angiotensin converting enzyme activity and expression is increased during hypoxic pulmonary hypertension. Cardiovasc Res 1997;34:393-403.
25. Morrell NW, Morris KG, Stenmark KR. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol 1995;269: H1186-H1194.
26. Johnson JA, West J, Maynard KB, Hemnes AR. ACE2 improves right ventricular function in a pressure overload model. PLoS One 2011;6:e20828.
27. Shenoy V, Ferreira AJ, Qi Y, et al. The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2010;182: 1065-1072.
28. Yamamoto K, Ohishi M, Katsuya T, et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 2006;47:718-726.
29. Ferreira AJ, Shenoy V, Yamazato Y, et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009;179:1048-1054.
30. Dempsey EC, Wick MJ, Karoor V, et al. Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia. Am J Pathol 2009;174:782-796.
31. Abraham WT, Raynolds MV, Badesch DB, et al. Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics. J Renin Angiotensin Aldosterone Syst 2003;4:27-30.
32. Rich S, Martinez J, Lam W, Rosen KM. Captopril as treatment for patients with pulmonary hypertension: problem of variability in assessing chronic drug treatment. Br Heart J 1982;48:272-277.
33. Leier CV, Bambach D, Nelson S, et al. Captopril in primary pulmonary hypertension. Circulation 1983;67:155-161.
34. Ikram H, Maslowski AH, Nicholls MG, Espiner EA, Hull FT. Haemodynamic and hormonal effects ofcaptopril in primary pulmonary hypertension. Br Heart J 1982;48:541-545.
35. Rossi GP. Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists? Curr Hypertens Rep 2006;8:262-268.
36. Jorde UP, Vittorio T, Katz SD, Colombo PC, Latif F, Le Jemtel TH. Elevated plasma aldosterone levels despite complete inhibition ofthe vascular angiotensin-converting enzyme in chronic heart failure. Circulation 2002; 106:1055-1057.
37. Maron BA, Zhang YY, White K, et al. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation 2012;126:963-974.
38. Maron BA, Opotowsky AR, Landzberg MJ, Loscalzo J, Waxman AB, Leopold JA. Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. Eur J Heart Fail 2013;15:277-283.
39. Maron BA, Waxman AB, Opotowsky AR, et al. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). Am J Cardiol 2013;112:720-725.
40. Funder JW. Cardiac synthesis of aldosterone: going, going, gone..? Endocrinology 2004;145:4793-4795.
41. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE. Origin of aldosterone in the rat heart. Endocrinology 2004;145:4796-4802.
42. Ye P, Kenyon CJ, MacKenzie SM, et al. The aldosterone syn-thase (CYP11B2) and 11beta-hydroxylase (CYP11B1) genes are not expressed in the rat heart. Endocrinology 2005;146: 5287-5293.
43. Takeda Y, Miyamori I, Yoneda T, et al. Regulation of aldo-sterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996;81:2797-2800.
44. Ahmad N, Romero DG, Gomez-Sanchez EP, Gomez-Sanchez CE. Do human vascular endothelial cells produce aldosterone? Endocrinology2004;145:3626-3629.
45. Takeda R, Hatakeyama H, Takeda Y, et al. Aldosterone biosynthesis and action in vascular cells. Steroids 1995;60:120-124.
46. Belloni AS, Rossi GP, Andreis PG, et al. Endothelin adre-nocortical secretagogue effect is mediated by the B receptor in rats. Hypertension 1996;27:1153-1159.
47. Preston IR, Sagliani KD, Warburton RR, Hill NS, Fanburg BL, Jaffe IZ. Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2013;304:L678-L688.
48. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-3019.
49. Shapiro S, Pollock DM, Gillies H, et al. Frequency ofedema in patients with pulmonary arterial hypertension receiving ambrisentan. Am J Cardiol 2012;110:1373-1377.
50. Briet M, Schiffrin EL. Vascular actions ofaldosterone. J Vasc Res 2013;50:89-99.
51. Nguyen Dinh Cat A, Jaisser F. Extrarenal effects of aldoste-rone. Curr Opin Nephrol Hypertens 2012;21:147-156.
52. Maron BA, Leopold JA. Mineralocorticoid receptor antagonists and endothelial function. Curr Opin Investig Drugs 2008;9:963-969.
53. Maron BA, Leopold JA. Aldosterone receptor antagonists: effective but often forgotten. Circulation 2010;121:934-939.
54. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002; 103:425-431.
55. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Cal-houn DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteron-ism. Circulation 2004;109:2857-2861.
56. Nagata D, Takahashi M, Sawai K, et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 2006;48:165-171.
57. Griol-Charhbili V, Fassot C, Messaoudi S, Perret C, Agra-part V, Jaisser F. Epidermal growth factor receptor mediates the vascular dysfunction but not the remodeling induced by aldosterone/salt. Hypertension 2011;57:238-244.
58. Leopold JA, Dam A, Maron BA, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehy-drogenase activity. Nat Med 2007;13:189-197.
59. Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res 2009;104:124-133.
60. Pessoa BS, Peixoto EB, Papadimitriou A, Lopes de Faria JM, Lopes de Faria JB. Spironolactone improves nephropa-thy by enhancing glucose-6-phosphate dehydrogenase activity and reducing oxidative stress in diabetic hypertensive rat. J Renin Angiotensin Aldosterone Syst 2012;13:56-66.
61. Bowers R, Cool C, Murphy RC, et al. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004;169:764-769.
62. Maron BA, Zhang YY, Handy DE, et al. Aldosterone increases oxidant stress to impair guanylyl cyclase activity by cysteinyl thiol oxidation in vascular smooth muscle cells. J Biol Chem 2009;284:7665-7672.
63. Shi G, Fu Y, Jiang W, et al. Activation ofSrc-ATF1 pathway is involved in upregulation of Nox1, a catalytic subunit of NADPH oxidase, by aldosterone. Endocr J 2011;58:491-499.
64. Fan C, Kawai Y, Inaba S, et al. Synergy of aldosterone and high salt induces vascular smooth muscle hypertrophy through up-regulation of NOX1. J Steroid Biochem Mol Biol 2008;111:29-36.
65. Cascella T, Radhakrishnan Y, Maile LA, et al. Aldosterone enhances IGF-I-mediated signaling and biological function in vascular smooth muscle cells. Endocrinology 2010;151: 5851-5864.
66. Kasal DA, Barhoumi T, Li MW, et al. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension 2012;59:324-330.
67. Caprio M, Newfell BG, la Sala A, et al. Functional mineral-ocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 2008;102:1359-1367.
68. Thum T, Schmitter K, Fleissner F, et al. Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. Eur Heart J 2011; 32:1275-1286.
69. Oberleithner H, Ludwig T, Riethmuller C, et al. Human endothelium: target for aldosterone. Hypertension 2004;43: 952-956.
70. Oberleithner H, Riethmuller C, Ludwig T, Hausberg M, Schillers H. Aldosterone remodels human endothelium. Acta Physiol (Oxf) 2006;187:305-312.
71. Kusche-Vihrog K, Callies C, Fels J, Oberleithner H. The epithelial sodium channel (ENaC): mediator of the aldoste-rone response in the vascular endothelium? Steroids 2010; 75:544-549.
72. Kusche-Vihrog K, Sobczak K, Bangel N, et al. Aldosterone and amiloride alter ENaC abundance in vascular endothe-lium. Pfluegers Arch 2008;455:849-857.
73. Fels J, Oberleithner H, Kusche-Vihrog K. Menage a trois: aldosterone, sodium and nitric oxide in vascular endothe-lium. Biochim Biophys Acta 2010;1802:1193-1202.
74. Azibani F, Benard L, Schlossarek S, et al. Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. Hypertension 2012;59:1179-1187.
75. Nakano S, Kobayashi N, Yoshida K, Ohno T, Matsuoka H. Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD (P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens Res 2005;28:925-936.
76. Favre J, Gao J, Zhang AD, et al. Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. Am J Physiol Heart Circ Physiol 2011; 300:H2035-H2043.
77. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005;111: 3025-3033.
78. Perrier R, Richard S, Sainte-Marie Y, et al. A direct relationship between plasma aldosterone and cardiac L-type Ca2+ current in mice. J Physiol 2005;569:153-162.
79. Gomez AM, Rueda A, Sainte-Marie Y, et al. Mineralocorti-coid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation 2009;119:2179-2187.
80. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993;27:341-348.
81. He BJ, Joiner ML, Singh MV, et al. Oxidation of Ca MKII determines the cardiotoxic effects of aldosterone. Nat Med 2011;17:1610-1618.
82. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119:2250-2294.
83. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-1263.
84. Delbeck M, Kretschmer A, Kast R, et al. Cardiorenal protection by BAY 94-8862, a novel non-steroidal miner-alocorticoid receptor antagonist in a preclinical model of hypertension and diastolic heart failure. Eur Heart J 2012; 33:772-773.
85. Barfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorti-coid receptor for the treatment of cardiorenal diseases. ChemMedChem 2012;7:1385-1403.
86. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013;34:2453-2463.
87. Elinoff JM, Rame JE, Forfia PR, et al. A pilot study of the effect of spironolactone therapy on exercise capacity and en-dothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial. Trials 2013; 14:91.
88. Hadri L, Kratlian RG, Benard L, et al. Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension. Circulation 2013;128:512-523.